Multi-year Revenue GrowthSustained top-line growth across multiple years provides a durable foundation: it signals market traction, supports scale economics, and creates capacity to invest in distribution and R&D. This revenue base improves resilience to cyclical shocks and funds strategic initiatives.

Stable Balance Sheet / Manageable LeverageA sound equity base and moderate debt profile give the company long-term financial flexibility to fund operations, capex, or selective M&A. Manageable leverage reduces default risk and preserves access to capital markets during industry cycles, supporting strategic continuity.

Historical Growth Supports OutlookA proven historical growth trajectory provides a platform for recovery and expansion even if margins temporarily compress. It indicates product-market fit and distribution capability that management can leverage to restore profitability and scale new product introductions over the medium term.

Bears Say

Margin CompressionSustained margin erosion reduces internal cash generation and weakens the firm's ability to finance growth or absorb cost shocks. In pharma, margin pressure can reflect pricing or cost issues that are structurally hard to reverse, making profitability restoration a medium-term challenge.

Volatile Free Cash FlowUnstable and recently negative free cash flow undermines the firm's capacity to fund capex, repay debt, or build reserves. Persistent volatility forces reliance on external financing, increasing financing costs and constraining long-term investment and operational flexibility.

Rising Leverage RiskA declining equity ratio signals reduced balance-sheet cushion and higher leverage exposure. If profitability and cash flows remain weak, even moderate debt can amplify risk, limiting strategic options and elevating refinancing or covenant pressures over the medium term.

Bafna Pharmaceuticals Limited News

Bafna Pharmaceuticals Files SEBI Dematerialisation Compliance Certificate for Q3 FY2025

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted to the stock...

2M ago

Bafna Pharmaceuticals Completes Sale of Chennai Manufacturing Unit

An update from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) is now available. Bafna Pharmaceuticals Limited has completed the...

8M ago

Bafna Pharmaceuticals Submits Annual SEBI Disclosure

Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ) has shared an update. Bafna Pharmaceuticals Limited has submitted its annual disclosure...

8M ago

Bafna Pharmaceuticals Announces Board and Committee Restructuring

The latest update is out from Bafna Pharmaceuticals Limited ( ($IN:BAFNAPH) ). Bafna Pharmaceuticals Limited announced the retirement...

9M ago

BAFNAPH FAQ

What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?

Bafna Pharmaceuticals Limited lowest stock price was ₹71.65 and its highest was ₹204.95 in the past 12 months.

What is Bafna Pharmaceuticals Limited’s market cap?

Bafna Pharmaceuticals Limited’s market cap is ₹2.55B.

When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?

Bafna Pharmaceuticals Limited’s upcoming earnings report date is Jun 03, 2026 which is in 85 days.

How were Bafna Pharmaceuticals Limited’s earnings last quarter?

Bafna Pharmaceuticals Limited released its earnings results on Feb 11, 2026. The company reported ₹0.776 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.776.

Is Bafna Pharmaceuticals Limited overvalued?

According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bafna Pharmaceuticals Limited pay dividends?

Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here

What is Bafna Pharmaceuticals Limited’s EPS estimate?

Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bafna Pharmaceuticals Limited have?

Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.

What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?

Bafna Pharmaceuticals Limited reported an EPS of ₹0.776 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.563%.

Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:BAFNAPH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bafna Pharmaceuticals Limited

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.